The Associated Press reports that the securities class action pending against Bristol-Myers Squibb Co. (NYSE: BMY) in the S.D.N.Y. has been dismissed with prejudice. The case alleged that Bristol-Myers and certain of its officers had made misrepresentations concerning the company’s accounting practices and its investment in ImClone Systems.
Search
-
Follow by RSS
Topics
Archives
Disclaimer
This blog is for informational purposes only. In other words, it does not constitute legal advice and is not intended to create an attorney-client relationship. Online readers should not act upon any information presented on this blog without seeking professional legal counsel. Finally, the posts on this blog represent the personal views of Lyle Roberts, not the views of his law firm or clients.
The author apologizes for any factual errors in this blog. Although he will act quickly to correct errors pointed out to him, he declines to take responsibility for the mischief that may result in the interim.
The 10b-5 Daily · News and events related to securities class action litigation. Containing all facts, with particularity, and an occasional dose of commentary.
The 10b-5 Daily 